<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352338</url>
  </required_header>
  <id_info>
    <org_study_id>RV-MM-PI-0630</org_study_id>
    <nct_id>NCT01352338</nct_id>
  </id_info>
  <brief_title>Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)</brief_title>
  <acronym>REPEAT</acronym>
  <official_title>A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Phase: phase 1 and phase 2

      Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in
      patients with relapsed multiple myeloma previously treated with lenalidomide

      Study design: prospective, multicenter, non-randomized
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The REPEAT-study is a prospective, multicenter, non-randomized phase 1 and phase 2 study in
      which we evaluate the effect of lenalidomide, cyclophosphamide and prednisone (REP-therapy)
      in patients with relapsed multiple myeloma, previously treated with lenalidomide and
      refractory to lenalidomide monotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT)</measure>
    <time_frame>29 days after start of treatment cycle 1</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and recommended phase 2 dose level (RDL) of lenalidomide administered during 21 days of a 4 weeks cycle, combined with continuous cyclophosphamide and prednisone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)</measure>
    <time_frame>29 days after start of treatment cycle 1</time_frame>
    <description>number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)</measure>
    <time_frame>28 days</time_frame>
    <description>- to evaluate progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)</measure>
    <time_frame>28 days</time_frame>
    <description>- to evaluate overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)</measure>
    <time_frame>28 days</time_frame>
    <description>- to evaluate the immunomodulatory effects of lenalidomide by using flow cytometric and cytokine analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>lenalidomide, endoxan, prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.
Lenalidomide is combined with endoxan and prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, endoxan, prednisone</intervention_name>
    <description>dose-finding</description>
    <arm_group_label>lenalidomide, endoxan, prednisone</arm_group_label>
    <other_name>revlimid combined with endoxan and prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide, endoxan, prednisone</intervention_name>
    <description>oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>lenalidomide, endoxan, prednisone</arm_group_label>
    <other_name>revlimid combined with cyclophosphamide and prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  salmon &amp; Durie stage II/III A or B

          -  previous lenalidomide refractory disease

          -  patient commits to pregnancy prevention programme

        Exclusion Criteria:

          -  non-secretory myeloma

          -  known hypersensitivity to lenalidomide

          -  inadequate marrow reserve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. N.C.W.J. Donk, van de, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>I.S. Nijhof</investigator_full_name>
    <investigator_title>Drs</investigator_title>
  </responsible_party>
  <keyword>REPEAT</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>revlimid</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>endoxan</keyword>
  <keyword>prednisone</keyword>
  <keyword>lenalidomide refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

